ALS treatment
adapted for
the real world

How will my patients take Teglutik®?

Teglutik® comes in a 300 ml bottle along with a reusable 10 ml syringe to help with accurate dosing.

Teglutik® works best when it is placed into the centre of the mouth, on the middle of the tongue, because it gives patients the best control over swallowing the medicine.

Teglutik® can be administered in 5 simple steps:1

Gently shake the bottle by turning it 180° for at least 30 seconds
Take the syringe, remove the tip and insert the syringe into the adaptor opening on the bottle
Turn the bottle upside down and pull the plunger down the fill the syringe with Teglutik®. Stop when the plunger reaches 10ml mark
Teglutik® works best when it is placed into the centre of the mouth, on the middle of the tongue, because it gives patients the best control over swallowing the medicine
Wash the syringe with water only and store Teglutik® safely

For detailed instructions on how to administer Teglutik®, please refer to the Patient Information Leaflet found in the Teglutik® packaging.

References:

  1. Teglutik® Patient Information Leaflet. Available at: https://www.medicines.org.uk/emc/medicine/31216. Last accessed: May 2016.

Welcome
to Teglutik®

Teglutik® is the first oral liquid suspension formulation of riluzole, the only licensed treatment for patients with amyotrophic lateral sclerosis (ALS), the most common type of motor neuron disease (MND).

This site provides information on Teglutik® and ALS for UK-based healthcare professionals and patients. Please select from the buttons below to tailor the content to your needs:

I am a UK healthcare professional
I am not a healthcare professional

For additional information about MND you can visit the Motor Neurone Disease Association website. The Motor Neurone Disease Association is the only national charity in England, Wales and Northern Ireland focused on MND care, research and campaigning

http://www.mndassociation.org/